News
US Food and Drug Administration Commissioner Marty Makary said he’s “taking a hard look” at whether a gene therapy from ...
The Food and Drug Administration plans to ask Sarepta Therapeutics Inc. to pause shipments of its Elevidys treatment after ...
A panel selected by FDA Commissioner Marty Makary, MD, MPH, unanimously urged the agency to remove the boxed warning on ...
22h
News Nation on MSNFDA chief: HRT warning among ‘greatest mistakes of modern medicine’( NewsNation) — The head of the U.S. Food and Drug Administration signaled Thursday that he supports changing or removing the ...
15h
Axios on MSNFDA panel backs menopausal hormone therapyAn Food and Drug Administration expert panel on Thursday endorsed removing the "black box" warning on hormone treatments for ...
Sarepta Therapeutics (NASDAQ:SRPT) shares dropped to a new 52-week low on Friday, triggering a trading halt after Bloomberg ...
1d
MedPage Today on MSNA 'Culture Change' Is Needed in Academic Medicine, FDA Commissioner SaysThe culture of academic medicine needs to change, FDA Commissioner Marty Makary, MD, MPH, said at an event sponsored by The ...
7h
Stocktwits on MSNFDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The MarketUS Food and Drug Administration Commissioner Marty Makary said he’s “taking a hard look” at whether Sarepta Therapeutics’ gene therapy, Elevidys, should remain on the market, following recent patient ...
FDA Commissioner Marty Makary's vision for the agency risks the best of an agency that mostly has functioned well for the ...
During a press conference on Monday, Food and Drug Administration Commissioner Marty Makary spoke about the agency's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results